Forge Investment Outlook Q2 2024Road to Recovery: Private Market Accelerates in Q1
Forge Investment Outlook Q2 2024
Trading
Data
Solutions
Insights
About
Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 9/9/2022 | Series C | $300MM raised | $XXX.XX | $XXX.XX |
| 11/16/2021 | Series B | $250MM raised | $XXX.XX | $XXX.XX |
| 12/15/2020 | Series A | $8MM raised | $XXX.XX | $XXX.XX |
